Literature DB >> 30679724

Structural similarity networks predict clinical outcome in early-phase psychosis.

Philipp Homan1,2,3, Miklos Argyelan4,5,6, Pamela DeRosse4,5,6, Philip R Szeszko7, Juan A Gallego4,5,6, Lauren Hanna4,5,6, Delbert G Robinson4,5,6, John M Kane4,5,6, Todd Lencz4,5,6, Anil K Malhotra4,5,6.   

Abstract

Despite recent advances, there is still a major need for prediction of treatment success in schizophrenia, a condition long considered a disorder of dysconnectivity in the brain. Graph theory provides a means to characterize the connectivity in both healthy and abnormal brains. We calculated structural similarity networks in each participant and hypothesized that the "hubness", i.e., the number of edges connecting a node to the rest of the network, would be associated with clinical outcome. This prospective controlled study took place at an academic research center and included 82 early-phase psychosis patients (23 females; mean age [SD] = 21.6 [5.5] years) and 58 healthy controls. Medications were administered in a double-blind randomized manner, and patients were scanned at baseline prior to treatment with second-generation antipsychotics. Symptoms were assessed with the Brief Psychiatric Rating Scale at baseline and over the course of 12 weeks. Nodal degree of structural similarity networks was computed for each subject and entered as a predictor of individual treatment response into a partial least squares (PLS) regression. The model fit was significant in a permutation test with 1000 permutations (P = 0.006), and the first two PLS regression components explained 29% (95% CI: 27; 30) of the variance in treatment response after cross-validation. Nodes loading strongly on the first PLS component were primarily located in the orbito- and prefrontal cortex, whereas nodes loading strongly on the second PLS component were primarily located in the superior temporal, precentral, and middle cingulate cortex. These data suggest a link between brain network morphology and clinical outcome in early-phase psychosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30679724      PMCID: PMC6461949          DOI: 10.1038/s41386-019-0322-y

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  64 in total

1.  Measurement in clinical trials: a neglected issue for statisticians?

Authors:  Stephen Senn; Steven Julious
Journal:  Stat Med       Date:  2009-11-20       Impact factor: 2.373

2.  Within-subject template estimation for unbiased longitudinal image analysis.

Authors:  Martin Reuter; Nicholas J Schmansky; H Diana Rosas; Bruce Fischl
Journal:  Neuroimage       Date:  2012-03-10       Impact factor: 6.556

3.  Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature.

Authors:  Christophe Destrieux; Bruce Fischl; Anders Dale; Eric Halgren
Journal:  Neuroimage       Date:  2010-06-12       Impact factor: 6.556

4.  A genomewide association study of citalopram response in major depressive disorder-a psychometric approach.

Authors:  Daniel E Adkins; Karolina Aberg; Joseph L McClay; John M Hettema; Susan G Kornstein; József Bukszár; Edwin J C G van den Oord
Journal:  Biol Psychiatry       Date:  2010-09-15       Impact factor: 13.382

5.  Functional connectivity and brain networks in schizophrenia.

Authors:  Mary-Ellen Lynall; Danielle S Bassett; Robert Kerwin; Peter J McKenna; Manfred Kitzbichler; Ulrich Muller; Ed Bullmore
Journal:  J Neurosci       Date:  2010-07-14       Impact factor: 6.167

6.  Disturbed grey matter coupling in schizophrenia.

Authors:  Guusje Collin; Marcel A de Reus; Wiepke Cahn; Hilleke E Hulshoff Pol; René S Kahn; Martijn P van den Heuvel
Journal:  Eur Neuropsychopharmacol       Date:  2012-10-01       Impact factor: 4.600

7.  Predicting Response to Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia Using Structural Magnetic Resonance Imaging: A Multisite Machine Learning Analysis.

Authors:  Nikolaos Koutsouleris; Thomas Wobrock; Birgit Guse; Berthold Langguth; Michael Landgrebe; Peter Eichhammer; Elmar Frank; Joachim Cordes; Wolfgang Wölwer; Francesco Musso; Georg Winterer; Wolfgang Gaebel; Göran Hajak; Christian Ohmann; Pablo E Verde; Marcella Rietschel; Raees Ahmed; William G Honer; Dominic Dwyer; Farhad Ghaseminejad; Peter Dechent; Berend Malchow; Peter M Kreuzer; Tim B Poeppl; Thomas Schneider-Axmann; Peter Falkai; Alkomiet Hasan
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

Review 8.  Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research.

Authors:  Paola Dazzan; Celso Arango; Wolfgang Fleischacker; Silvana Galderisi; Birte Glenthøj; Stephan Leucht; Andreas Meyer-Lindenberg; Rene Kahn; Dan Rujescu; Iris Sommer; Inge Winter; Philip McGuire
Journal:  Schizophr Bull       Date:  2015-03-23       Impact factor: 7.348

9.  Mastering variation: variance components and personalised medicine.

Authors:  Stephen Senn
Journal:  Stat Med       Date:  2015-09-28       Impact factor: 2.373

Review 10.  The dysconnection hypothesis (2016).

Authors:  Karl Friston; Harriet R Brown; Jakob Siemerkus; Klaas E Stephan
Journal:  Schizophr Res       Date:  2016-07-20       Impact factor: 4.939

View more
  5 in total

1.  Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis.

Authors:  Philipp Homan; Miklos Argyelan; Christina L Fales; Anita D Barber; Pamela DeRosse; Philip R Szeszko; Delbert G Robinson; Todd Lencz; Anil K Malhotra
Journal:  Neuropsychopharmacology       Date:  2019-07-17       Impact factor: 7.853

2.  Individual-specific networks for prediction modelling - A scoping review of methods.

Authors:  Mariella Gregorich; Federico Melograna; Martina Sunqvist; Stefan Michiels; Kristel Van Steen; Georg Heinze
Journal:  BMC Med Res Methodol       Date:  2022-03-06       Impact factor: 4.615

3.  ECT-induced cognitive side effects are associated with hippocampal enlargement.

Authors:  Miklos Argyelan; Todd Lencz; Simran Kang; Sana Ali; Paul J Masi; Emily Moyett; Andrea Joanlanne; Philip Watson; Sohag Sanghani; Georgios Petrides; Anil K Malhotra
Journal:  Transl Psychiatry       Date:  2021-10-08       Impact factor: 6.222

4.  Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance.

Authors:  Maria S Neumeier; Stephanie Homan; Stefan Vetter; Erich Seifritz; John M Kane; Maximilian Huhn; Stefan Leucht; Philipp Homan
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 7.348

5.  Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study.

Authors:  Paola Dazzan; Andrew J Lawrence; Antje A T S Reinders; Alice Egerton; Neeltje E M van Haren; Kate Merritt; Gareth J Barker; Rocio Perez-Iglesias; Kyra-Verena Sendt; Arsime Demjaha; Kie W Nam; Iris E Sommer; Christos Pantelis; W Wolfgang Fleischhacker; Inge Winter van Rossum; Silvana Galderisi; Armida Mucci; Richard Drake; Shon Lewis; Mark Weiser; Covadonga M Martinez Diaz-Caneja; Joost Janssen; Marina Diaz-Marsa; Roberto Rodríguez-Jimenez; Celso Arango; Lone Baandrup; Brian Broberg; Egill Rostrup; Bjørn H Ebdrup; Birte Glenthøj; Rene S Kahn; Philip McGuire
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 7.348

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.